Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares.On Thursday Sinclair purchased one round of 8.075m shares at 1.59p a time and a second lot of 1.41m shares at 1.42p each for a total of £148,429. Friday's purchase saw him buy 8.25m shares at an average price of 1.655p each, costing £136,538 altogether. Earlier in the week the group announced that it has signed a definitive share purchase agreement for the acquisition of 100% of the share capital of ADAM, a business focused on radiotherapy and proton therapy. ADAM is being purchased for a consideration to the vendor of stock and warrants in Advanced Oncotherapy that will be equivalent to 29.9% of the issued ordinary share capital and warrants of the company prior to the completion of the transaction.Top Director BuysF&C Asset Management (FCAM) Director name: Mr Richard Wilson Amount purchased: 351,672 @ 95.80p Value: £336,902Advanced Oncotherapy (AVO) Director name: Dr Michael SinclairAmount purchased: 8,250,000 @ 1.66p Value: £136,125PureCircle Ltd. (DI) (PURE) Director name: Mr John SlosarAmount purchased: 20,000 @ 256.00p Value: £51,200Vernalis (VER) Director name: Mr Nigel SheailAmount purchased: 107,000 @ 23.00p Value: £24,610Verona Pharma (VRP) Director name: Mr Stuart BottomlyAmount purchased: 1,000,000 @ 2.15p Value: £21,500Nasstar (NASA) Director name: Mr Maurice EveAmount purchased: 190,476 @ 10.50p Value: £20,000Tesco (TSCO) Director name: Mr Olivia Garfield Amount purchased: 4,086 @ 365.20p Value: £14,922Top Director SellsPortmeirion Group (PMP) Director name: Mr B.W.J. PhillipsAmount sold: 51,823 @ 610.00p Value: £316,120